edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
Healthcare
The agreement with Bristol Myers Squibb (BMS) is for BioArctic’s PyroGlutamate-amyloid-beta (PyroGlu-Aβ) antibody programme, which includes the candidates BAN1503 and BAN2803, the latter of which covers BioArctic’s BrainTransporter technology. Deal terms include an upfront payment of US$100m and up to US$1.25bn in milestone payments, alongside low double-digit percentage royalties on global product sales.
Industrials | Comment
TMT | Comment
Industrials | Comment
Industrials | Comment
Get access to the very latest content matched to your personal investment style.